Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NS-229 in Eosinophilic Granulomatosis With Polyangiitis
NCT06046222Phase 2Active, not recruiting
- Sponsor
- NS Pharma, Inc.
- Start
- Dec 2023
- Primary completion
- Dec 2026
- Modality
- Small Molecules
- Countries
- 8
01
Overview
Phase 2, randomised, double-blind trial in eosinophilic granulomatosis with polyangiitis (EGPA) comparing NS-229 with Placebo (2 arms). Primary endpoint: Proportion of subjects in remission [OGC 4.0] at 28 weeks. Started Dec 2023; status: active, not recruiting.
02
Drugs
NS-229
03
Conditions
eosinophilic granulomatosis with polyangiitis (EGPA)
Beyond the preview
Go deeper on NCT06046222.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06046222.